2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh risk
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply